There are 142 resources available
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session
Resources:
Webcast
Why are we having this Symposium? Recent regulatory actions by FDA/EMEA regarding late-stage approval for PARPi in recurrent ovarian cancer
Presenter: Robert Coleman
Session: How to interpret overall survival data with PARP inhibitors
Resources:
Slides
Webcast
Is there clinical evidence to support the link between PARPi use and a negative impact on OS?
Presenter: Jonathan Ledermann
Session: How to interpret overall survival data with PARP inhibitors
Resources:
Slides
Webcast
Is there a biological rationale to support decremental impact on overall survival?
Presenter: Antonio Jose Gonzalez Martin
Session: How to interpret overall survival data with PARP inhibitors
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: How to interpret overall survival data with PARP inhibitors
Resources:
Webcast
Welcome to the ESMO Gynaecological Cancers Congress 2023
Presenter: The Chairs
Session: Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023
Resources:
Slides
Webcast
Introduction
Presenter: Susana Banerjee
Session: Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023
Resources:
Webcast
Do we still need radical surgery in the PARP inhibitor era?
Presenter: GIOVANNI Scambia
Session: Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023
Resources:
Slides
Webcast
How to select the best first line maintenance treatment? Is molecular profiling the only criteria to choose?
Presenter: Isabelle Ray-Coquard
Session: Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023
Resources:
Slides
Webcast
New treatment in the current ovarian cancer beyond ADCs
Presenter: Nicoletta Colombo
Session: Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023
Resources:
Slides
Webcast